HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Mankind Pharma inks pact to acquire 100% stake in BSV
Jul-26-2024

Mankind Pharma has entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines (BSV) from Advent International (Advent), one of the world’s largest and most experienced private equity investors, for an enterprise value of approximately Rs 13,630 crore, subject to closing related adjustments. This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women's health and fertility drug market alongside access to other high entry barrier products in critical care with established complex R&D tech platforms.

With over five decades of leadership in biopharmaceuticals, BSV has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across Women's Health, Fertility and Critical Care, with a few of its marque brands enjoying a strong leadership position in their respective therapy areas. BSV’s dedicated inhouse R&D centre along with a dedicated team of 60 plus scientists, a strong product pipeline, coupled with a diverse domestic product portfolio offering huge scalability potential through niche filings across markets. 

Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

  RELATED NEWS >>